[1]
Chavhan, S.S.; Petkar, K.C.; Sawant, K.K. Nanosuspensions in drug delivery: Recent advances, patent scenarios, and commercialization aspects. Crit. Rev. Ther. Drug Carrier Syst., 2011, 28(5), 447-488.
[2]
Liu, Y.; Xie, P.; Zhang, D.; Zhang, Q. A mini review of nanosuspensions development. J. Drug Target., 2012, 20(3), 209-223.
[3]
Shah, D.A.; Murdande, S.B.; Dave, R.H. A review: Pharmaceutical and pharmacokinetic aspect of nanocrystalline suspensions. J. Pharm. Sci., 2016, 105(1), 10-24.
[4]
Carrier, R.L.; Miller, L.A.; Ahmed, I. The utility of cyclodextrins for enhancing oral bioavailability. J. Control. Release, 2007, 123(2), 78-99.
[5]
Mishra, I. Dendrimer: A novel drug delivery system. J. Drug Deliv. Thera., 2011, 1(2), 333-392.
[6]
Chaudhary, A.; Nagaich, U.; Gulati, N.; Sharma, V.K.; Khosa, R.L. Enhancement of solubilization and bioavailability of poorly soluble drugs by physical and chemical modifications: A recent review JAPER, 2012, 2(1), 32-67.
[7]
Junghanns, J.U.; Muller, R.H. Nanocrystal technology, drug delivery and clinical applications. Int. J. Nanomed., 2008, 3(3), 295-309.
[8]
Patravale, V.; Date, A.; Kulkarni, R. Nanosuspensions: A promising drug delivery strategy. J. Pharm. Pharmacol., 2004, 56, 827-840.
[9]
Vishal, P.; Abhale, V.N. Nanocrystal technology: A particle engineering formulation strategy for the poorly water soluble drugs. Pharm. Lett, 2016, 8, 384-392.
[10]
Prabhakar, C.; Krishna, K. A review on nanosuspensions in drug delivery. Int. J. Pharm. Bio. Sci., 2011, 2, 549-558.
[11]
Peltonen, L.; Hirvonen, J. Pharmaceutical nanocrystals by nanomilling: Critical process parameters, particle fracturing and stabilization methods. J. Pharm. Pharmacol., 2010, 62(11), 1569-1579.
[12]
Chogale, M.M.; Ghodake, V.N.; Patravale, V.B. Performance parameters and characterizations of nanocrystals: A brief review. Pharmaceutics, 2016, 8(3) E26
[13]
Zhou, Y.; Du, J.; Wang, L.; Wang, Y. Nanocrystals technology for improving bioavailability of poorly soluble drugs: A mini-review. J. Nanosci. Nanotechnol., 2017, 17(1), 18-28.
[14]
Boles, M.A.; Ling, D.; Hyeon, T.; Talapin, D.V. The surface science of nanocrystals. Nat. Mater., 2016, 15(2), 141-153.
[15]
Kumar, S.; Dilbaghi, N.; Rani, R.; Bhanjana, G. Nanotechnology as emerging tool for enhancing solubility of poorly water-soluble drugs. BioNanoScience, 2012, 2, 4.
[17]
Burda, C.; Chen, X.; Narayanan, R.; El-Sayed, M.A. Chemistry and properties of nanocrystals of different shapes. Chem. Rev., 2005, 105(4), 1025-1102.
[18]
Sutradhar, K.; Khatun, S.; Luna, I. Increasing possibilities of nanosuspension. J. Nanotechnol., 2013, 2013 346581
[19]
Gora, S.; Mustafa, G.; Sahni, J.K.; Ali, J.; Baboota, S. Nanosizing of valsartan by high pressure homogenization to produce dissolution enhanced nanosuspension: Pharmacokinetics and pharmacodyanamic study. Drug Deliv., 2016, 23(3), 940-950.
[21]
Salazar, J.; ller, R.H.; Schwitzer, J.P. Combinative particle size reduction technologies for the production of drug nanocrystals. J. Pharm. (Cairo), 2014, 2014, 14.
[22]
Patrignani, F.; Lanciotti, R. Applications of high and ultra high pressure homogenization for food safety. Front. Microbiol., 2016, 7, 1132.
[23]
de Waard, H.; Frijlink, H.W.; Hinrichs, W.L.J. Bottom-up preparation techniques for nanocrystals of lipophilic drugs. Pharm. Res., 2011, 28(5), 1220-1223.
[24]
Chang, T-l.; Zhan, H.; Liang, D.; Liang, J. Nanocrystal technology for drug formulation and delivery. Front Chem. Sci. Eng, 2015, 9, 1-14.
[25]
Prasanna, L.; Giddam, A.K. Nano-suspension technology: A review. Int. J. Pharm. Pharm. Sci., 2010, 2, 35-40.
[26]
Geetha, G.; Poojitha, U.; Khan, A. Various techniques for preparation of nanosuspension-a review. Pharm. Res., 2014, 3, 30-37.
[27]
de Waard, H.; De Beer, T.; Hinrichs, W.L.; Vervaet, C.; Remon, J.P.; Frijlink, H.W. Controlled crystallization of the lipophilic drug fenofibrate during freeze-drying: Elucidation of the mechanism by in-line Raman spectroscopy. AAPS J., 2010, 12(4), 569-575.
[28]
Moschwitzer, J.; Muller, R.H. New method for the effective production of ultrafine drug nanocrystals. J. Nanosci. Nanotechnol., 2006, 6(9-10), 3145-3153.
[29]
Chin, W.W.; Parmentier, J.; Widzinski, M.; Tan, E.H.; Gokhale, R. A brief literature and patent review of nanosuspensions to a final drug product. J. Pharm. Sci., 2014, 103(10), 2980-2999.
[30]
Shegokar, R.; Muller, R.H. Nanocrystals: Industrially feasible multifunctional formulation technology for poorly soluble actives. Int. J. Pharm., 2010, 399(1-2), 129-139.
[31]
Salazar, J.; Muller, R.H.; Moschwitzer, J.P. Performance comparison of two novel combinative particle-size-reduction technologies. J. Pharm. Sci., 2013, 102(5), 1636-1649.
[32]
Teagarden, D.L.; Baker, D.S. Practical aspects of lyophilization using non-aqueous co-solvent systems. Eur. J. Pharm. Sci., 2002, 15(2), 115-133.
[33]
Shete, G.; Bansal, A.K. NanoCrySP technology for generation of drug nanocrystals: Translational aspects and business potential. Drug Deliv. Transl. Res., 2016, 6(4), 392-398.
[34]
Bansal, S.; Kumria, R. Nanocrystals: Current strategies and trends. Int. J. Res. Pharmaceut. Biomed. Sci., 2012, 3(1), 407-419.
[35]
Jacobs, C.; Muller, R.H. Production and characterization of a budesonide nanosuspension for pulmonary administration. Pharm. Res., 2002, 19(2), 189-194.
[36]
Bhatia, S. Natural polymer drug delivery systems: Nanoparticles, plants, and algae. In: Nanoparticles, Plants, and Algae; Switzerland: Springer International Publishing, 2016; pp. 1-225.
[37]
Blunk, T.; Hochstrasser, D.F.; Sanchez, J.C.; Muller, B.W.; Muller, R.H. Colloidal carriers for intravenous drug targeting: Plasma protein adsorption patterns on surface-modified latex particles evaluated by two-dimensional polyacrylamide gel electrophoresis. Electrophoresis, 1993, 14(12), 1382-1387.
[38]
Blunk, T.; Luck, M.; Calvor, A.; Hochstrasser, D.F.; Sanchez, J.C.; Muller, B.W.; Muller, R.H. Kinetics of plasma protein adsorption on model particles for controlled drug delivery and drug targeting. Eur. J. Pharm. Biopharm., 1996, 42, 262-268.
[39]
Wallis, K.H.; Muller, R.H. Determination of the surface hydrophobicity of colloidal dispersions by mini-hydrophobic interaction chromatography. Pharm. Ind., 1993, 55, 1124-1128.
[40]
Kocbek, P.; Baumgartner, S.; Kristl, J. Preparation and evaluation of nanosuspensions for enhancing the dissolution of poorly soluble drugs. Int. J. Pharm., 2006, 312(1-2), 179-186.
[41]
Tuomela, A.; Hirvonen, J.; Peltonen, L. Stabilizing agents for drug nanocrystals: Effect on bioavailability. Pharmaceutics, 2016, 8(2), 16.
[42]
Lai, F.; Pini, E.; Angioni, G.; Manca, M.L.; Perricci, J.; Sinico, C.; Fadda, A.M. Nanocrystals as tool to improve piroxicam dissolution rate in novel orally disintegrating tablets. Eur. J. Pharm. Biopharm., 2011, 79(3), 552-558.
[43]
Tuomela, A. Nanocrystals for Drug Delivery Applications.
Doctoral dissertation (article-based), University of Helsinki. 2015.
[44]
Abdelwahed, W.; Degobert, G.; Stainmesse, S.; Fessi, H. Freeze-drying of nanoparticles: formulation, process and storage considerations. Adv. Drug Deliv. Rev., 2006, 58(15), 1688-1713.
[45]
Nagalingam, A.; Deecaraman, M.; Rani, C. Nanosuspension Technology and its applications in drug delivery. Asian J. Pharmaceut, 2009, 3, 3.
[46]
Kayser, O.; Olbrich, C.; Yardley, V.; Kiderlen, A.F.; Croft, S.L. Formulation of amphotericin B as nanosuspension for oral administration. Int. J. Pharm., 2003, 254(1), 73-75.
[47]
Mauludin, R.; Muller, R.H.; Keck, C.M. Development of an oral rutin nanocrystal formulation. Int. J. Pharm., 2009, 370(1-2), 202-209.
[48]
Merisko-Liversidge, E.; Liversidge, G.G.; Cooper, E.R. Nanosizing: A formulation approach for poorly-water-soluble compounds. Eur. J. Pharm. Sci., 2003, 18(2), 113-120.
[49]
Kayser, O. Nanosuspensions for the formulation of aphidicolin to improve drug targeting effects against leishmania infected macrophages. Int. J. Pharm., 2000, 196(2), 253-256.
[50]
Gao, L.; Liu, G.; Ma, J.; Wang, X.; Zhou, L.; Li, X. Drug nanocrystals: In vivo performances. J. Control. Release, 2012, 160(3), 418-430.
[51]
Chingunpituk, J. Nanosuspension technology for drug delivery. Walailak J. Sci. Technol., 2011, 4(2), 15.
[52]
Rabinow, B.E. Nanosuspensions for parenteral delivery. In: Nanoparticulate Drug Delivery Systems; Thassu, M.D.; Pathak, Y., Eds.; Informa Healthcare: London, 2015; pp. 33-49.
[53]
Zhang, Q.; Shen, Z.; Nagai, T. Prolonged hypoglycemic effect of insulin-loaded polybutylcyanoacrylate nanoparticles after pulmonary administration to normal rats. Int. J. Pharm., 2001, 218(1-2), 75-80.
[54]
Gao, L.Z.; Dianrui, Z.; Chen, M. Drug nanocrystals for the formulation of poorly soluble drugs and its application as a potential drug delivery system. J. Nanopart. Res., 2008, 10, 845-862.
[55]
Kassem, M.A.; Abdel Rahman, A.A.; Ghorab, M.M.; Ahmed, M.B.; Khalil, R.M. Nanosuspension as an ophthalmic delivery system for certain glucocorticoid drugs. Int. J. Pharm., 2007, 340(1-2), 126-133.
[56]
Romero, G.B.; Keck, C.M.; Muller, R.H.; Bou-Chacra, N.A. Development of cationic nanocrystals for ocular delivery. Eur. J. Pharm. Biopharm., 2016, 107, 215-222.
[57]
Katara, R.; Sachdeva, S.; Majumdar, D.K. Design, characterization, and evaluation of aceclofenac-loaded Eudragit RS 100 nanoparticulate system for ocular delivery. Pharm. Dev. Technol., 2019, 24(3), 368-379.
[58]
Pignatello, R.; Ricupero, N.; Bucolo, C.; Maugeri, F.; Maltese, A.; Puglisi, G. Preparation and characterization of Eudragit Retard nanosuspensions for the ocular delivery of cloricromene. AAPS PharmSciTech, 2006, 7(1), E192-E198.
[59]
Lu, Y.; Li, Y.; Wu, W. Injected nanocrystals for targeted drug delivery. Acta. Pharm., 2016, 6(2), 106-113.
[60]
Hao, L.; Luan, J.; Zhang, D.; Li, C.; Guo, H.; Qi, L.; Liu, X.; Li, T.; Zhang, Q. Research on the in vitro anticancer activity and in vivo tissue distribution of Amoitone B nanocrystals. Colloids Surf. B Biointerfaces, 2014, 117, 258-266.
[61]
Han, M.; Liu, X.; Guo, Y.; Wang, Y.; Wang, X. Preparation, characterization, biodistribution and antitumor efficacy of hydroxycamptothecin nanosuspensions. Int. J. Pharm., 2013, 455(1-2), 85-92.
[62]
Schöler, N.; Krause, K.; Kayser, O.; Müller, R.H.; Borner, K.; Hahn, H.; Liesenfeld, O. Atovaquone nanosuspensions show excellent therapeutic effect in a new murine model of reactivated toxoplasmosis. Antimicrob. Agents Chemother., 2001, 45(6), 1771-1779.
[63]
Bhusnure, O.G.; Gholve, S.B.; Bhange, M.M.; Pentewar, R.S. Formulation of nanosuspension and nanoemulsion as a new approach for the delivery of poorly soluble drugs. IAJPR, 2015, 5(11), 11.
[64]
Taheri, A.; Mohammadi, M. The use of cellulose nanocrystals for potential application in topical delivery of hydroquinone. Chem. Biol. Drug Des., 2015, 86(1), 102-106.
[65]
Pyo, S.; Meinke, M.; Keck, C.; Müller, R. Rutin—Increased antioxidant activity and skin penetration by nanocrystal technology (smartCrystals). Cosmetics, 2016, 3(1), 9.
[66]
Kobierski, S.; Ofori-Kwakye, K.; Muller, R.H.; Keck, C.M. Resveratrol nanosuspensions for dermal application--production, characterization, and physical stability. Pharmazie, 2009, 64(11), 741-747.
[67]
Pathak, D.T.; Deleers, M. Pharmaceutical applications of nanoparticulate drug-delivery systems. In: Nanoparticulate Drug Delivery Systems; Informa Healthcare: London, 2015; pp. 185-212.
[68]
Hecq, J.; Deleers, M.; Fanara, D.; Vranckx, H.; Amighi, K. Preparation and characterization of nanocrystals for solubility and dissolution rate enhancement of nifedipine. Int. J. Pharm., 2005, 299(1-2), 167-177.
[69]
Lockman, P.R.; Koziara, J.M.; Mumper, R.J.; Allen, D.D. Nanoparticle surface charges alter blood-brain barrier integrity and permeability. J. Drug Target., 2004, 12(9-10), 635-641.
[70]
Alyautdin, R.N.; Petrov, V.E.; Langer, K.; Berthold, A.; Kharkevich, D.A.; Kreuter, J. Delivery of loperamide across the blood-brain barrier with polysorbate 80-coated polybutyl-cyanoacrylate nanoparticles. Pharm. Res., 1997, 14(3), 325-328.
[71]
Schroder, U.; Sabel, B.A. Nanoparticles, a drug carrier system to pass the blood-brain barrier, permit central analgesic effects of i.v. dalargin injections. Brain Res., 1996, 710(1-2), 121-124.
[72]
Muller, R.H.; Jacobs, C. Buparvaquone mucoadhesive nanosuspension: Preparation, optimisation and long-term stability. Int. J. Pharm., 2002, 237(1-2), 151-161.
[73]
Möschwitzer, J.; Müller, R.H. Spray coated pellets as carrier system for mucoadhesive drug nanocrystals. Eur. J. Pharm. Biopharm., 2006, 62(3), 282-287.
Download PDF Flyer